drugset
drugset / Trial / NCT04389801

Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

NCT04389801 ↗

Phase 4 Unknown 200 enrolled Hesham Al-Inany
RandomizedParallel-groupSingle-blindTreatment

Summary

To evaluate the efficacy of using Desferal injections for prevention of ARDS in moderate cases with fever , chest tightness and relevant chest images

Timeline

Start
2020-06-01
Primary completion
2020-09-30
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Deferoxamine Other / unclassified 500 mg —

Indications

COVID-19